Inhibition of vascular inflammation by dehydroepiandrosterone sulfate in human aortic endothelial cells: Roles of PPARα and NF-κB

Vascular Pharmacology

Volumn 48, Issue 2-3, 2008, Pages 76-84

  Altman, Robin ^a   Motton, Deborah D ^b   Kota, Rama S ^a   Rutledge, John C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dehydroepiandrosterone sulfate; Endothelial cell; Inflammation; PPAR; VCAM

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 8; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PRASTERONE SULFATE; VASCULAR CELL ADHESION MOLECULE 1;

AORTA; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL DAMAGE; DISEASE COURSE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR UPREGULATION;

AORTA; AROMATASE INHIBITORS; CELL SURVIVAL; DEHYDROEPIANDROSTERONE SULFATE; ENDOTHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-8; NF-KAPPA B; NITRILES; PPAR ALPHA; SIGNAL TRANSDUCTION; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 40149090943     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2007.12.002     Document Type: Article

References (48)

1. Adams J., Garcia M., and Rochefort H. Estrogenic effects of physiological concentrations of 5-androstene-3 beta, 17 beta-diol and its metabolism in MCF7 human breast cancer cells. Cancer Res. 41 11 Pt 1 (1981) 4720-4726
2. Alexandersen P., Haarbo J., and Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 125 (1996) 1-13
3. Aragno M., Parola S., Brignardello E., Mauro A., Tamagno E., Manti R., Danni O., and Boccuzzi G. Dehydroepiandrosterone prevents oxidative injury induced by transient ischemia/reperfusion in the brain of diabetic rats. Diabetes 49 (2000) 1924-1931
4. Ayhan S., Tugay C., Norton S., Araneo B., and Siemionow M. Dehydroepiandrosterone protects the microcirculation of muscle flaps from ischemia-reperfusion injury by reducing the expression of adhesion molecules. Plast. Reconstr Surg. 111 (2003) 2286-2294
5. Barbagallo M., Shan J., Pang P.K., and Resnick L.M. Effects of dehydroepiandrosterone sulfate on cellular calcium responsiveness and vascular contractility. Hypertension 26 (1995) 1065-1069
6. Barrett-Connor E., Khaw K.T., and Yen S.S.C. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N. Engl. J. Med. 315 (1986) 1519-1524
7. Baulieu E.E., Corp'echot C., Dray F., Emiliozzi R., Lebeau M.C., Mauvais-Jarvis P., and Robel P. An adrenal-secreted "androgen": dehydroepiandrosterone sulfate, its metabolism and a tentative generalization on the metabolism of other steroid conjugates in man. Recent Prog. Horm Res. 21 (1965) 411-500
8. Bodine P.V., Riggs B.L., and Spelsberg T.C. Regulation of c-fos expression and TGF-beta production by gonadal and adrenal androgens in normal human osteoblastic cells. J. Steroid Biochem. Mol Biol. 52 (1995) 149-158
9. Celec P., and Starka L. Dehydroepiandrosterone - is the fountain of youth drying out?. Physiol. Res. 52 4 (2003) 397-407
10. Contoreggi C.S., Backman M.R., Anders R., Muller C.D., Lakatta E.G., Fleg J.L., and Harman S.M. Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men. J. Androl. 11 (1990) 460-470
11. Delerive P., De Bosscher K., Besnard S., Vanden Berghe W., Peters J.M., Gonzalez F.J., Fruchart J.C., Tedgui A., Haegeman G., and Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274 45 (1999) 32048-32054
12. Dufort I., Soucy P., Lacoste L., and Luu-The V. Comparative biosynthetic pathway of androstenol and androgens. J. Steroid Biochem. Mol Biol. 77 4-5 (2001) 223-227
13. Gordon G.B., Bush D.E., and Weisman H.F. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. J. Clin. Invest. 82 (1988) 712-720
14. Haning Jr. R.V., Carlson I.H., Flood C.A., Hackett R.J., and Longcope C. Metabolism of dehydroepiandrosterone sulfate (DS) in normal women and women with high DS concentrations. J. Clin. Endocrinol. Metab. 73 (1991) 1210-1215
15. Harada N., Sasano H., Murakami H., Ohkuma T., Nagura H., and Takagi Y. Localized expression of aromatase in human vascular tissues. Circ. Res. 84 (1999) 1285-1291
16. Hayashi T., Esaki T., Muto E., Kano H., Asai Y., Thakur N.K., Sumi D., Jayachandran M., and Iguchi A. Dehydroepiandrosterone retards atherosclerosis formation through its conversion to estrogen: the possible role of nitric oxide. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 782-792
17. Hornsby P.J. Biosynthesis of DHEAS by the human adrenal cortex and its age-related decline. Ann. N. Y. Acad. Sci. 774 (1995) 29-46
18. Iwasaki Y., Asai M., Yoshida M., Nigawara T., Kambayashi M., and Nakashima N. Dehydroepiandrosterone-sulfate inhibits nuclear factor-kappaB-dependent transcription in hepatocytes, possibly through antioxidant effect. J. Clin. Endocrinol. Metab. 89 7 (2004) 3449-3454 Jul
19. Johannes C.B., Stellato R.K., Feldman H.A., Longcope C., and McKinlay J.B. Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. J. Clin. Epidemiol. 52 2 (1999) 95-103 Feb
20. Khaw K.T. Dehydroepiandrosterone, dehydroepiandrosterone sulphate and cardiovascular disease. J. Endocrinol. 150 (1996) S149-S153 Suppl
21. Kota R.S., Ramana C.V., Tenorio F.A., Enelow R.I., and Rutledge J.C. Differential effects of lipoprotein lipase on tumor necrosis factor-α and interferon-γ-mediated gene expression in human endothelial cells. J. Biol. Chem. 280 (2005) 31076-31084
22. LaCroix A.Z., Yano K., and Reed D.M. Dehydroepiandrosterone sulfate, incidence of myocardial infarction, and extent of atherosclerosis in men. Circulation 86 (1992) 1529-1535
23. Lea-Currie Y.R., Wu S.M., and McIntosh M.K. Effects of acute administration of dehydroepiandrosterone-sulfate on adipose tissue mass and cellularity in male rats. Int. J. Obes. Relat. Metab. Disord. 21 (1997) 147-154
24. Liu D., and Dillon J.S. Dehydroepiandrosterone activates endothelial cell nitric-oxide synthase by a specific plasma membrane receptor coupled to Galpha(i2,3). J. Biol. Chem. 277 (2002) 21379-21388
25. Liu D., and Dillon J.S. Dehydroepiandrosterone stimulates nitric oxide release in vascular endothelial cells: evidence for a cell surface receptor. Steroids 69 4 (2004) 279-289 Apr
26. Marx N. Peroxisome proliferator-activated receptor gamma and atherosclerosis. Curr. Hypertens. Rep. 4 (2002) 71-77
27. Marx N., Schonbeck U., Lazar M.A., Libby P., and Plutzky J. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ. Res. 83 (1998) 1097-1103
28. Marx N., Sukhova G.K., Collins T., Libby P., and Plutzky J. PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
29. Mastrocola R., Aragno M., Betteto S., Brignardello E., Catalano M.G., Danni O., and Boccuzzi G. Pro-oxidant effect of dehydroepiandrosterone in rats is mediated by PPAR activation. Life Sci. 73 (2003) 289-299
30. Meikle A.W., Dorchuck R.W., Araneo B.A., Stringham J.D., Evans T.G., Spruance S.L., and Daynes R.A. The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J. Steroid Biochem. Mol Biol. 42 (1992) 293-304
31. Neve B.P., Fruchart J.C., and Staels B. Role of the peroxisome proliferator-activated receptors (PPAR) in atherosclerosis. Biochem Pharmacol. 60 (2000) 1245-1250
32. Newcomer L.M., Manson J.E., Barbieri R.L., Hennekens C.H., and Stampfer M.J. Dehydroepiandrosterone sulfate and the risk of myocardial infarction in US male physicians: a prospective study. Am. J. Epidemiol. 140 (1994) 870-875
33. Orentreich N., Brind J.L., Rizer R.L., and Vogelman J.H. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J. Clin. Endocrinol. Metab. 59 3 (1984) 551-555
34. Peters J.M., Zhou Y.C., Ram P.A., Lee S.S., Gonzalez F.J., and Waxman D.J. Peroxisome proliferator-activated receptor alpha required for gene induction by dehydroepiandrosterone-3 beta-sulfate. Mol. Pharmacol. 50 (1996) 67-74
35. Porsova-Dutoit I., Sulcova J., and Starka L. Do DHEA/DHEAS play a role in coronary heart disease?. Physiol. Res. 49 Suppl. 1 (2000) S43-S56
36. Poynter M.E., and Daynes R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-kappaB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem. 273 (1998) 32833-32841
37. Provost P.R., Blomquist C.H., Godin C., Huang X.F., Flamand N., Luu-The V., Nadeau D., and Tremblay Y. Androgen formation and metabolism in the pulmonary epithelial cell line A549: expression of 17beta-hydroxysteroid dehydrogenase type 5 and 3alpha-hydroxysteroid dehydrogenase type 3. Endocrinology 141 8 (2000) 2786-2794
38. Regelson W., and Kalimi M. Dehydroepiandrosterone (DHEA)-the multifunctional steroid. II. Effects on the CNS, cell proliferation, metabolic and vascular, clinical and other effects. Mechanism of action?. Ann. N. Y. Acad. Sci. 719 (1994) 564-575
39. Rival Y., Beneteau N., Taillandier T., Pezet M., Dupont-Passelaigue E., Patoisseau J.F., Junquero D., Colpaert F.C., and Delhon A. PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1-1 in EAhy926 endothelial cells. Eur. J. Pharmacol. 435 2-3 (2002) 143-151
40. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
41. Sambrook J., and Russell D.W. Molecular Cloning: A Laboratory Manual. Third Edition (2001), Cold Spring Harbor
42. Sharma R.V., Gurjar M.V., and Bhalla R.C. Selected contribution: estrogen receptor-alpha gene transfer inhibits proliferation and NF-kappaB activation in VSM cells from female rats. J. Appl. Physiol. 91 (2001) 2400-2406 discussion 2389-2390
43. Shaul P.W. Endothelial nitric oxide synthase, caveolae and the development of atherosclerosis. J. Physiol. 547 (2003) 21-33
44. Simoncini T., Maffei S., Basta G., Barsacchi G., Genazzani A.R., Liao J.K., and De Caterina R. Estrogens and glucocorticoids inhibit endothelial vascular cell adhesion molecule-1 expression by different transcriptional mechanisms. Circ. Res. 87 (2000) 19-25
45. Taniguchi S., Yanase T., Kobayashi K., Takayanagi R., and Nawata H. Dehydroepiandrosterone markedly inhibits the accumulation of cholesteryl ester in mouse macrophage J774-1 cells. Atherosclerosis 126 (1996) 143-154
46. Vanden Berghe W., Vermeulen L., Delerive P., De Bosscher K., Staels B., and Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv. Exp. Med. Biol. 544 (2003) 181-196
47. Wen Y., Yang S., Liu R., Perez E., Yi K.D., Koulen P., and Simpkins J.W. Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res. 1008 (2004) 147-154
48. Williams M.R., Ling S., Dawood T., Hashimura K., Dai A., Li H., Liu J.P., Funder J.W., Sudhir K., and Komesaroff P.A. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J. Clin. Endocrinol. Metab. 87 (2002) 176-181